Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy

Kim, Isaac Yi; Mitrofanova, Antonina; Panja, Sukanya; Sterling, Joshua; Srivastava, Arnav; Kim, Juliana; Kim, Sinae; Singer, Eric A.; Jang, Thomas L.; Ghodoussipour, Saum; Saraiya, Biren; Mayer, Tina; Sabaawy, Hatem E.; Yuh, Bertram; Byun, Seok Soo; Kim, Wun-Jae; Horie, Shigeo

doi:10.1016/j.prnil.2022.03.001

Cited by 8 publications

(12 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Different potential stimuli, such as microbial infections, chemical irritations, diet, obesity, and physical traumas, can promote the status of chronic inflammation. A pathogenic shift in the microbial species’ composition of the intraprostatic and genitourinary tracts, or dysbiosis, could lead directly or indirectly to an inflammatory state predisposing to the loss of the epithelial barrier integrity [ 11 , 18 , 19 ]. In turn, epithelial damage triggers an immune system response leading to the recruitment of the inflammatory cells, oxidative stress and the consequent DNA damage, compensatory epithelial proliferation, establishing a feed-forward mechanism promoting prostatic intraepithelial neoplasia ( Figure 1 ).…”

Section: Microbiome Inflammation and Prostate Cancermentioning

confidence: 99%

Microbiome and Prostate Cancer: A Novel Target for Prevention and Treatment

Kuštrimović

Bombelli

Baci

et al. 2023

IJMS

View full text Add to dashboard Cite

Growing evidence of the microbiome’s role in human health and disease has emerged since the creation of the Human Microbiome Project. Recent studies suggest that alterations in microbiota composition (dysbiosis) may play an essential role in the occurrence, development, and prognosis of prostate cancer (PCa), which remains the second most frequent male malignancy worldwide. Current advances in biological technologies, such as high-throughput sequencing, transcriptomics, and metabolomics, have enabled research on the gut, urinary, and intra-prostate microbiome signature and the correlation with local and systemic inflammation, host immunity response, and PCa progression. Several microbial species and their metabolites facilitate PCa insurgence through genotoxin-mediated mutagenesis or by driving tumor-promoting inflammation and dysfunctional immunosurveillance. However, the impact of the microbiome on PCa development, progression, and response to treatment is complex and needs to be fully understood. This review addresses the current knowledge on the host–microbe interaction and the risk of PCa, providing novel insights into the intraprostatic, gut, and urinary microbiome mechanisms leading to PCa carcinogenesis and treatment response. In this paper, we provide a detailed overview of diet changes, gut microbiome, and emerging therapeutic approaches related to the microbiome and PCa. Further investigation on the prostate-related microbiome and large-scale clinical trials testing the efficacy of microbiota modulation approaches may improve patient outcomes while fulfilling the literature gap of microbial–immune–cancer-cell mechanistic interactions.

show abstract

Section: Microbiome Inflammation and Prostate Cancermentioning

confidence: 99%

Microbiome and Prostate Cancer: A Novel Target for Prevention and Treatment

Kuštrimović

Bombelli

Baci

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…11,[31][32][33][34][35] Several prospective and clinical studies have additionally confirmed that cytoreductive prostatectomy can significantly improve the progression-free survival (PFS) and CSS of patients with mPCa, delaying disease progression while enhancing the quality of life. [36][37][38] A contentious debate surrounds the efficacy of lymph node dissection during radical prostatectomy for prostate cancer. The feasibility, therapeutic outcomes, and optimal extent of lymph node dissection remain uncertain.…”

Section: Cytoreductive Prostatectomy Patients Exhibit Improved Surviv...mentioning

confidence: 99%

“…The value of CRP as a local treatment has thus remained controversial, emphasizing a need for further RCTs focused on this interventional approach using strict inclusion criteria. 14 As the above results emphasize, CRP can contribute to good survival outcomes in appropriate patient populations 36,37 but may not achieve the desired effects when applied in patients who fail to meet screening criteria while exposing these individuals to an unnecessary risk of complications. 38 Prospective studies have employed variable screening criteria (Table 1).…”

Section: Indications For Cytoreductive Prostatectomymentioning

confidence: 99%

“…Considering the high probability of urological severe complications in patients with mPCa, the acceptability of this risk was determined for most patients. 37 Simforoosh et al found that in addition to improving urinary complications, CRP was also associated with reductions in bone pain. Specifically, 14 patients (53.8%) reported significant improvements in bone pain after CRP compared to just 3 in the standard treatment group, while 11 patients (47.8%) experienced new or aggravated bone pain.…”

Section: Cytoreductive Prostatectomy Can Alleviate Local Urinary Trac...mentioning

confidence: 99%

See 1 more Smart Citation

Current Controversy and Developments Regarding the Cytoreductive Prostatectomy for Oligometastatic Prostate Cancer

Tian,

Mao,

Tang

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Oligometastatic prostate cancer is a term that is most often used to refer to limited sites of disseminated tumor growth following primary radical prostatectomy (RP) or radiotherapy (RT), while de novo oligometastatic is a term that is used to refer to prostate tumors that have disseminated to limited sites before definitive treatment. In patients with de novo oligometastatic prostate cancer, treatment planning must thus consider the need to manage the primary tumor and the associated distant lesions. Traditionally, resectioning primary metastatic tumors is not thought to offer significant benefits to affected patients while increasing their risk of surgery-related complications. Recent clinical evidence indicates that patients undergoing cytoreductive prostatectomy (CRP) may observe substantial enhancements in overall survival rates while not experiencing a noticeable decline in their quality of life. Nevertheless, based on the current body of evidence, it is deemed inadequate to justify revising clinical guidelines. Consequently, it is not advisable to propose CRP for patients with oligometastatic prostate cancer. The present review was compiled to summarize available data regarding the indications, functional outcomes, and oncological outcomes associated with cytoreductive radical prostatectomy to provide a robust and objective foundation that can be used to better assess the value of this interventional strategy from a clinical perspective.

show abstract

“…In addition, CRP provides molecular pathologists with sufficient tissue for genetic testing, which is becoming increasingly crucial in metastatic PCa. 77 Nonetheless, due to the lack of data, RT is still considered the primary local treatment for newly diagnosed, low-volume mHSPC. 9 , 15…”

Section: Treatment Of the Primarymentioning

confidence: 99%